Development of thymic tumor in [LSL:Kras G12D ; Pdx1-CRE] mice, an adverse effect associated with accelerated pancreatic carcinogenesis
Abstract Pancreatic Ductal AdenoCarcinoma (PDAC) represents about 90% of pancreatic cancers. It is one of the most aggressive cancer, with a 5-year survival rate below 10% due to late diagnosis and poor therapeutic efficiency. This bad prognosis thus encourages intense research in order to better un...
Main Authors: | Sophie Liot, Naïma El Kholti, Jonathan Balas, Laurent Genestier, Bernard Verrier, Ulrich Valcourt, Elise Lambert |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-07-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-94566-x |
Similar Items
-
Loss of Tenascin-X expression during tumor progression: A new pan-cancer marker
by: Sophie Liot, et al.
Published: (2020-05-01) -
Inhibition of Pancreatic Intraepithelial Neoplasia Progression to Carcinoma by Nitric Oxide-Releasing Aspirin in p48Cre/+-LSL-KrasG12D/+ Mice
by: Chinthalapally V. Rao, et al.
Published: (2012-09-01) -
Endogenous n-3 Polyunsaturated Fatty Acids Delay Progression of Pancreatic Ductal Adenocarcinoma in Fat-1-p48Cre/+-LSL-KrasG12D/+ Mice
by: Altaf Mohammed, et al.
Published: (2012-12-01) -
The Mouse Model of Pancreatic Cancer Atlas (MMPCA) for classification of pancreatic cancer lesions: A large histological investigation of the Ptf1aCre/+;LSL-KrasG12D/+ transgenic mouse model of pancreatic cancer.
by: Michelle J Veite-Schmahl, et al.
Published: (2017-01-01) -
Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine Kras(G12D)-induced skin carcinogenesis in vivo.
by: Pawel K Mazur, et al.
Published: (2010-01-01)